Jul 1, 8:14 PM
BIOGEN $BIIB DISCLOSES R&D, MILESTONE CHARGES IMPACTING Q2, Q3 ADJ EPS
Biogen expects charges from acquired in-process R&D, upfront and milestone payments, tied to business development deals, to affect adjusted diluted EPS, per an SEC filing:
- Q2 2026: ~$164M in charges, a
BIIB